Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

Terminated

Phase 2 Results N/A

Summary of Purpose

The primary objective of the study is to assess the safety and tolerability of Human Placenta-Derived Cells (PDA001) at 3 different dose levels versus placebo (vehicle control) administered intravenously in subjects following ischemic stroke. The secondary objective of the study is to assess the effect of PDA001 on... Trial Stopped: Study terminated by sponsor

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 30 March 2016.

1 Mar 2011 25 Feb 2011 1 Mar 2013 1 Mar 2013 1 Mar 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts